Basic Information
BOOSTAGEN SUSPENSION FOR INJECTION
INJECTION, SUSPENSION
Regulatory Information
SIN16493P
May 18, 2022
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07AJ52
Company Information
Active Ingredients
Strength: 7.5 Lf/0.5 ml
Strength: 2.0 Lf/0.5 ml
Strength: 5 ug/0.5 ml
Strength: 5 ug/0.5 ml
Detailed Information
Contraindications
**CONTRAINDICATION** **Boostagen** ® should not be administered to individuals with past experience or signs of: - hypersensitivity or life-threatening reaction following administration of diphtheria, tetanus or pertussis vaccines or to any components of the vaccine (see Section COMPOSITION – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_); - any encephalopathy with unknown aetiology such as coma, prolonged seizures, or decreased level of consciousness within 7 days following previous vaccination with any whooping cough vaccine; - progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy.
Indication Information
**INDICATION** **Boostagen** ® is indicated for: - active booster immunization against tetanus, diphtheria and pertussis in individuals from the age of 3 years onwards. - maternal immunization in pregnant women for the prevention of pertussis in infants too young to be vaccinated. **Boostagen** ® is not indicated for primary immunization.